News

A letter to Secretary Kennedy on behalf of of the undersigned organizations representing the nation’s clinical and public health laboratories.

Clinical and Laboratory Standards Institute is thrilled to celebrate CLSI Board President Dr. James Nichols, for his recognition as recipient of the 2025 IFCC Award for Distinguished Contributions in Education.

CLSI has partnered with the LymeX Diagnostics Prize to support Phase 4 teams advancing Lyme disease diagnostics. Teams will implement their clinical validation plans and complete regulatory submissions to the FDA to accelerate the development of Lyme disease diagnostics.

The Clinical and Laboratory Standards Institute (CLSI) is pleased to welcome Zahra Shajani-Yi, PhD, DABCC, FADLM to the CLSI Board of Directors.

The Clinical and Laboratory Standards Institute (CLSI) is pleased to announce the recipients of the 2025 CLSI Excellence Awards.

The Clinical and Laboratory Standards Institute (CLSI) announced today the formation of a new Laboratory-Developed Test (LDT) Final Rule Advisory Group. The group, comprising 15 respected subject matter experts in laboratory medicine and regulatory policy, is scheduled to convene for the first time in mid-December 2024

CLSI shares standards guidance to support teams competing for innovation prize for the development of new point-of-care lead detection tests.

CLSI and bioMérieux launch a Global Symposium in Tokyo to advance antimicrobial susceptibility testing (AST).

The Clinical and Laboratory Standards Institute (CLSI) is pleased to announce the recipients of its 2024 Excellence Awards. The Excellence Awards recognize the achievements of CLSI volunteers and organizational members who are committed to CLSI’s mission and have helped improve the quality of medical care worldwide. Recipients are recognized for dedicating significant time and effort to the development, implementation, and promotion of CLSI standards.

In 1972, CLSI, formerly known as the National Committee for Clinical Laboratory Standards (NCCLS), published “Table 1” in one of the earliest NCCLS AST documents. Table 1 was intended to help clinical laboratories decide which antimicrobial agents to test and report on specific bacteria. New drugs and new comments were added to the Tables 1 over the ensuing decades, but the format for these tables did not change.